Quarterly report [Sections 13 or 15(d)]

In-licensing and Acquisition (Details)

v3.26.1
In-licensing and Acquisition (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
May 11, 2026
Feb. 22, 2024
Jun. 30, 2026
Jul. 31, 2024
Dec. 31, 2022
Jul. 31, 2022
Jun. 30, 2026
Jun. 30, 2026
Dec. 31, 2022
Dec. 31, 2025
 [1]
Asset Acquisition [Line Items]                    
Estimated useful life               13 years 8 months 12 days    
Acquisition-related liabilities     $ 218       $ 218 $ 218   $ 5,000
Accounts payable     4,011       4,011 $ 4,011   $ 7,191
GAVRETO (pralsetinib)                    
Asset Acquisition [Line Items]                    
Estimated useful life   12 years                
REZLIDHIA                    
Asset Acquisition [Line Items]                    
Estimated useful life               14 years    
Blueprint | GAVRETO (pralsetinib)                    
Asset Acquisition [Line Items]                    
Asset acquisition, expected price   $ 15,000                
Purchase consideration   15,400                
Acquisition payment   15,000   $ 10,000            
Transaction costs   $ 400                
Acquisition-related liabilities     5,000       5,000 $ 5,000    
Blueprint | GAVRETO (pralsetinib) | Minimum                    
Asset Acquisition [Line Items]                    
Potential tiered royalties   10.00%                
Blueprint | GAVRETO (pralsetinib) | Maximum                    
Asset Acquisition [Line Items]                    
Potential tiered royalties   30.00%                
Regulatory milestones | Blueprint | GAVRETO (pralsetinib)                    
Asset Acquisition [Line Items]                    
Potential milestone payments   $ 5,000                
Commercial milestones | Blueprint | GAVRETO (pralsetinib)                    
Asset Acquisition [Line Items]                    
Potential milestone payments   97,500                
First commercial sale | Blueprint | GAVRETO (pralsetinib)                    
Asset Acquisition [Line Items]                    
Asset acquisition, expected price   10,000                
First anniversary of the closing date | Blueprint | GAVRETO (pralsetinib)                    
Asset Acquisition [Line Items]                    
Asset acquisition, expected price   $ 5,000                
FDA approval and first commercial sale of product | REZLIDHIA                    
Asset Acquisition [Line Items]                    
Accounts payable         $ 15,000       $ 15,000  
Arvinas And Pfizer                    
Asset Acquisition [Line Items]                    
Upfront fee $ 85,000   70,000              
Potential payments 15,000                  
Intangible assets capitalized     $ 70,600              
Estimated useful life     15 years              
Arvinas And Pfizer | Regulatory milestones                    
Asset Acquisition [Line Items]                    
Potential payments 60,000                  
Arvinas And Pfizer | Commercial milestones                    
Asset Acquisition [Line Items]                    
Potential payments 260,000                  
Arvinas And Pfizer | Ongoing development activities                    
Asset Acquisition [Line Items]                    
Potential payments $ 40,000                  
Research and development             $ 1,500 $ 1,500    
Forma                    
Asset Acquisition [Line Items]                    
Upfront fee           $ 2,000        
Research and development                 $ 2,000  
Forma | Commercial milestones                    
Asset Acquisition [Line Items]                    
Potential payments           165,500        
Forma | Development and regulatory milestones                    
Asset Acquisition [Line Items]                    
Potential payments           $ 67,500        
Forma | Achievement of certain near-term regulatory milestone                    
Asset Acquisition [Line Items]                    
Research and development         $ 2,500          
[1] The balance sheet at December 31, 2025 has been derived from the audited financial statements included in Rigel’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (SEC) on March 3, 2026.